Oncothyreon highlights corporate and clinical objectives for 2008
The Phase 3 pivotal trial of Stimuvax in patients with non-small cell lung cancer (NSCLC), START (Stimulating Targeted Antigenic Responses To NSCLC), continues enrollment in 2008. This year Oncothyreon expects to manufacture and to continue to provide to Merck KGaA substantial quantities of both Stimuvax and placebo to support START and potentially other additional trials of Stimuvax. In addition, Oncothyreon will continue the development of a large-scale process in preparation for the manufacture of commercial quantities of Stimuvax. Oncothyreon expects to receive an additional milestone payment related to Stimuvax during 2008.
This entry was posted on Monday, January 28th, 2008 at 9:09 am and is filed under Research, Non-Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.